Teva Pharmaceutical Introduces Nicardipine Hydrochloride Injection
More News related to TEVA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Teva Receives Final Approval for Generic Prevacid(R) Delayed-Release Capsules
- Teva Pharma (TEVA) Announces Generic Version of Prevacid Does Not Infringe on Patents
- Teva Receives Favorable Court Decision Regarding Generic Prevacid(R) SoluTab
- Teva Pharma (TEVA) Seeks to Amend Existing Complaint Against Momenta Pharma over Copaxone Patent Infringement
More News related to Corporate News
- Citigroup (C) Kelly Making Comments At Banking Conference: "Balance Sheet is Very Liquid"
- Rockwell Collins (COL) Awarded $450M U.S. Navy Contract for ARC-210 Radios
- Alvarion (ALVR) Selected by Adam Internet to Deploy WiMAX Network in Adelaide, Australia
- AEterna Zentaris (AEZS) Reports That Perifosine Partner Keryx Biopharma (KERX) Will Prersent Data from Phase 1/2 at 51st ASH Meeting
- Geron Corp. (GERN) Reports that hESC-Derived Oligodendrocyte Progenitor Cells Reduced Cervical Spinal Cord Injury
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced the introduction of Nicardipine Hydrochloride Injection, 2.5 mg/mL, which is AP-rated to EKR Therapeutics' hypertension treatment Cardene(R) I.V. Teva's product is the first alternative to the brand product, which had annual sales of approximately $181 million in the United States for the twelve months ended June 30, 2008, according to IMS sales data.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company.[SM]
Related Categories
Corporate NewsStocks Mentioned
+0.13Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
